Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JAK inhibitors
Pharma
Sanofi inks $1.5B deal for Sino Biopharm's novel asset
Sanofi is committing $1.53 billion to license a first-in-class JAK/ROCK inhibitor from Sino Biopharm with eyes on both hematology and immunology.
Angus Liu
Mar 4, 2026 3:00am
Incyte expands awards program to hidradenitis suppurativa
Nov 6, 2025 10:00am
New Incyte CEO takes 'fresh look' at business, outlines BD plan
Aug 4, 2025 11:16am
Alfasigma's JAK inhibitor Jyseleca scores in phase 3 trial
Jul 29, 2025 8:50am
China biotech deals, Takeda, LaNova—Fierce Pharma Asia
Jul 18, 2025 9:04am
Sun Pharma beats Incyte in appeals, teeing up US alopecia launch
Apr 10, 2025 10:00am
